Refine
Has Fulltext
- yes (24)
Is part of the Bibliography
- yes (24)
Document Type
- Journal article (24)
Language
- English (24)
Keywords
- adrenocortical carcinoma (5)
- CYP2W1 (2)
- Cushing’s syndrome (2)
- FGFR (2)
- SOAT1 (2)
- adrenal tumours (2)
- immunotherapy (2)
- machine learning (2)
- metabolomics (2)
- 18F-FDG (1)
- 2-deoxy-2-(18F)fluoro-D-glucose (1)
- ACTH (1)
- CRH stimulation test (1)
- CTNNB1 (1)
- CXCR4 (1)
- CXCR7 (1)
- CYP2B6 (1)
- Cushing syndrome (1)
- Cushing's disease (1)
- Cushing’s disease (1)
- EMT (1)
- FGF-pathway (1)
- NCI-H295R (1)
- NR3C1 (1)
- PD-L1 (1)
- PET (1)
- Positronen-Emissions-Tomografie (1)
- RNA Expression (1)
- RNAScope (1)
- SNP (1)
- TKI (1)
- USP8 (1)
- [18F]FDG-PET-CT (1)
- abdominal lymph node metastases (1)
- adjuvant platinum-based chemotherapy (1)
- adrenal (1)
- adrenal glands (1)
- adrenal imaging (1)
- adrenocortical carcinoma (ACC) (1)
- adrenocortical tissues (1)
- adrenocortical tumors (1)
- amphiphilic block copolymer (1)
- autonomous cortisol secretion (1)
- biomarker (1)
- biomarkers (1)
- cancer treatment (1)
- carcinomas (1)
- cardiovascular events (1)
- cardiovascular risk factors (1)
- catecholamines (1)
- chemokine receptor (1)
- cholesterol metabolism (1)
- combination (1)
- confounders (1)
- dexamethasone suppression test (1)
- diagnosis (1)
- drug therapy (1)
- ectopic (1)
- endogenous hypercortisolism (1)
- epithelial markers (1)
- feature selection (1)
- glucocorticoid excess (1)
- high dose dexamethasone suppression test (1)
- hormones (1)
- hypercortisolism (1)
- hypertension (1)
- immune check inhibitor (1)
- immune checkpoint inhibitor (ICI) (1)
- immune response (1)
- immunity (1)
- immunohistochemistry (1)
- immunohistochemistry techniques (1)
- lymphocytes (1)
- mass spectronomy (1)
- medullary thyroid cancer (1)
- medullary thyroid carcinoma (1)
- mesenchymal markers (1)
- mitotane (1)
- molecular diagnostics (1)
- morbidity (1)
- mortality (1)
- multi-tyrosine kinase inhibitor (1)
- multicenter (1)
- mutation triggers (1)
- normal adrenal glands (1)
- papillary thyroid carcinoma (PTC) (1)
- paraganglioma (1)
- parathyroid carcinoma (1)
- patient survival (1)
- pembrolizumab (1)
- personalized medicine (1)
- pheochromocytoma (1)
- pheochromocytoma/paraganglioma (1)
- phosphorylation (1)
- plasma NMR (1)
- poly(2-oxazoline) (1)
- positron emission tomography (1)
- preanalytical conditions (1)
- predictive marker (1)
- primary aldosteronism (1)
- prognosis (1)
- prognostic factors (1)
- prostate cancer (1)
- radical resection (1)
- radioiodine (1)
- radiotherapy (RT) (1)
- rearranged during transfection (1)
- recurrence-free survival (1)
- repeated surgery (1)
- selpercatinib (1)
- solubility enhancement (1)
- surgical oncology (1)
- survival (1)
- t-lymphocytes (1)
- target therapies (1)
- targeted metabolomics (1)
- thyroid carcinoma (TC) (1)
- treatment outcome (1)
- tumor microenvironment (1)
- tumor-infiltrating (1)
- tyrosine kinase inhibitor (1)
- tyrosine kinase inhibitor (TKI) (1)
- unsupervised clustering (1)
- vandetanib (1)
- variant (1)
Institute
- Medizinische Klinik und Poliklinik I (24) (remove)
Sonstige beteiligte Institutionen
Impact of the Chemokine Receptors CXCR4 and CXCR7 on Clinical Outcome in Adrenocortical Carcinoma
(2020)
Chemokine receptors have a negative impact on tumor progression in several human cancers and have therefore been of interest for molecular imaging and targeted therapy. However, their clinical and prognostic significance in adrenocortical carcinoma (ACC) is unknown. The aim of this study was to evaluate the chemokine receptor profile in ACC and to analyse its association with clinicopathological characteristics and clinical outcome. A chemokine receptor profile was initially evaluated by quantitative PCR in 4 normal adrenals, 18 ACC samples and human ACC cell line NCI-H295. High expression of CXCR4 and CXCR7 in both healthy and malignant adrenal tissue and ACC cells was confirmed. In the next step, we analyzed the expression and cellular localization of CXCR4 and CXCR7 in ACC by immunohistochemistry in 187 and 84 samples, respectively. These results were correlated with clinicopathological parameters and survival outcome. We detected strong membrane expression of CXCR4 and CXCR7 in 50% of ACC samples. Strong cytoplasmic CXCR4 staining was more frequent among samples derived from metastases compared to primaries (p=0.01) and local recurrences (p=0.04). CXCR4 membrane staining positively correlated with proliferation index Ki67 (r=0.17, p=0.028). CXCR7 membrane staining negatively correlated with Ki67 (r=−0.254, p=0.03) but positively with tumor size (r=0.3, p=0.02). No differences in progression-free or overall survival were observed between patients with strong and weak staining intensities for CXCR4 or CXCR7. Taken together, high expression of CXCR4 and CXCR7 in both local tumors and metastases suggests that some ACC patients might benefit from CXCR4/CXCR7-targeted therapy.
Despite considerable morbidity and mortality, numerous cases of endocrine hypertension (EHT) forms, including primary aldosteronism (PA), pheochromocytoma and functional paraganglioma (PPGL), and Cushing’s syndrome (CS), remain undetected. We aimed to establish signatures for the different forms of EHT, investigate potentially confounding effects and establish unbiased disease biomarkers. Plasma samples were obtained from 13 biobanks across seven countries and analyzed using untargeted NMR metabolomics. We compared unstratified samples of 106 PHT patients to 231 EHT patients, including 104 PA, 94 PPGL and 33 CS patients. Spectra were subjected to a multivariate statistical comparison of PHT to EHT forms and the associated signatures were obtained. Three approaches were applied to investigate and correct confounding effects. Though we found signatures that could separate PHT from EHT forms, there were also key similarities with the signatures of sample center of origin and sample age. The study design restricted the applicability of the corrections employed. With the samples that were available, no biomarkers for PHT vs. EHT could be identified. The complexity of the confounding effects, evidenced by their robustness to correction approaches, highlighted the need for a consensus on how to deal with variabilities probably attributed to preanalytical factors in retrospective, multicenter metabolomics studies.
Mitotane is the only approved drug for advanced adrenocortical carcinoma (ACC) and no biomarkers are available to predict attainment of therapeutic plasma concentrations and clinical response. Aim of the study was to evaluate the suitability of cytochrome P450(CYP)2W1 and CYP2B6 single nucleotide polymorphisms (SNPs) as biomarkers. A multicenter cohort study including 182 ACC patients (F/M = 121/61) treated with mitotane monotherapy after radical resection (group A, n = 103) or in not completely resectable, recurrent or advanced disease (group B, n = 79) was performed. CYP2W1*2, CYP2W1*6, CYP2B6*6 and CYP2B6 rs4803419 were genotyped in germline DNA. Mitotane blood levels were measured regularly. Response to therapy was evaluated as time to progression (TTP) and disease control rate (DCR). Among investigated SNPs, CYP2W1*6 and CYP2B6*6 correlated with mitotane treatment only in group B. Patients with CYP2W1*6 (n = 21) achieved less frequently therapeutic mitotane levels (>14 mg/L) than those with wild type (WT) allele (76.2% vs 51.7%, p = 0.051) and experienced shorter TTP (HR = 2.10, p = 0.019) and lower DCR (chi-square = 6.948, p = 0.008). By contrast, 55% of patients with CYP2B6*6 vs. 28.2% WT (p = 0.016) achieved therapeutic range. Combined, a higher rate of patients with CYP2W1*6WT+CYP2B6*6 (60.6%) achieved mitotane therapeutic range (p = 0.034). In not completely resectable, recurrent or advanced ACC, CYP2W1*6 SNP was associated with a reduced probability to reach mitotane therapeutic range and lower response rates, whereas CYP2B6*6 correlated with higher mitotane levels. The association of these SNPs may predict individual response to mitotane.
Background
Treatment options for poorly differentiated (PDTC) and anaplastic (ATC) thyroid carcinoma are unsatisfactory and prognosis is generally poor. Lenvatinib (LEN), a multi-tyrosine kinase inhibitor targeting fibroblast growth factor receptors (FGFR) 1-4 is approved for advanced radioiodine refractory thyroid carcinoma, but response to single agent is poor in ATC. Recent reports of combining LEN with PD-1 inhibitor pembrolizumab (PEM) are promising.
Materials and Methods
Primary ATC (n=93) and PDTC (n=47) tissue samples diagnosed 1997-2019 at five German tertiary care centers were assessed for PD-L1 expression by immunohistochemistry using Tumor Proportion Score (TPS). FGFR 1-4 mRNA was quantified in 31 ATC and 14 PDTC with RNAscope in-situ hybridization. Normal thyroid tissue (NT) and papillary thyroid carcinoma (PTC) served as controls. Disease specific survival (DSS) was the primary outcome variable.
Results
PD-L1 TPS≥50% was observed in 42% of ATC and 26% of PDTC specimens. Mean PD-L1 expression was significantly higher in ATC (TPS 30%) than in PDTC (5%; p<0.01) and NT (0%, p<0.001). 53% of PDTC samples had PD-L1 expression ≤5%. FGFR mRNA expression was generally low in all samples but combined FGFR1-4 expression was significantly higher in PDTC and ATC compared to NT (each p<0.001). No impact of PD-L1 and FGFR 1-4 expression was observed on DSS.
Conclusion
High tumoral expression of PD-L1 in a large proportion of ATCs and a subgroup of PDTCs provides a rationale for immune checkpoint inhibition. FGFR expression is low thyroid tumor cells. The clinically observed synergism of PEM with LEN may be caused by immune modulation.